Objective To compare the characteristics/management of acute venous thromboembolism
(VTE) for patients either discharged directly from the emergency department (ED) or …

Abstract Background Direct oral anticoagulants (DOACs) have shown comparable efficacy
and a superior safety profile in clinical trials for patients with venous thromboembolism …

Background: Anticoagulation in patients with pulmonary embolism. Objective: To identify
how non-vitamin K antagonist oral anticoagulants are associated with multiple outcomes in …

Importance Extending the duration of oral anticoagulation for venous thromboembolism
(VTE) beyond the initial 3 to 6 months of treatment is often recommended, but it is not clear …

Venous thromboembolism (VTE) is a serious medical condition associated with significant
morbidity and mortality, and an incidence that is expected to double in the next forty years …

Purpose This study aims to review the published literature concerning the use of novel oral
anticoagulants (NOACs) in the treatment and prevention of venous thromboembolism (VTE) …

Optimal long-term anticoagulation post-PE should be guided by straightforward and
individual risk assessment strategies. The array of indications for DOACs has gotten wider in …

Pulmonary embolism (PE) is a leading cause of mortality worldwide. Recognizing PE and
administering anticoagulants can significantly improve patient outcomes by reducing …

Background: Little data exist on the use of direct oral anticoagulant (DOAC) factor Xa
inhibitors for submassive pulmonary embolism (PE) after catheter-directed thrombolysis …

Background Pulmonary embolism (PE) is a critical condition requiring effective management
strategies. Several options are available, including thrombolytic therapy and anticoagulants …